



# EAU25 | MADRID, SPAIN

21-24 March 2025

Cutting-edge Science at Europe's largest Urology Congress

## Rules and regulations late-breaking abstract submission

### Definition:

A late-breaking abstract is an abstract that contains new information that is not yet known or fully available by the original annual abstract submission deadline, 1 November, 08:30 CET.

### Criteria:

The research must be novel, innovative, contemporary, and of high scientific significance. Abstracts should describe either large, prospective clinical investigations or high-impact translational research.

At the end of the submission, authors are required to provide a rationale in the question section, explaining why they believe their abstract meets the late-breaking criteria.

**Before entering the abstract submission system you are requested to carefully read the following rules.**

### Deadline:

Deadline for the submission of late breaking abstracts is **3 February 2025, 23:59 Central European Time (CET)**. Submit in time to avoid that your abstract cannot be submitted due to technical issues. Only abstracts submitted through the official online submission system will be considered. Please note. Make sure you only use Google Chrome (latest version).

*Note, the late-breaking abstract deadline is not an extension of the submission deadline.*

Until this deadline you will be able to:

- make changes in your abstract or author list, even when already submitted
- withdraw abstracts

After this submission deadline:

- there is no possibility to edit abstracts anymore
- to withdraw your submitted abstracts you should send an email to [abstracts@congressconsultants.com](mailto:abstracts@congressconsultants.com)

### Submission timeline:

- Deadline submission: **3 February 2025, 23:59 CET** via the EAU25 abstract submission website. Select presentation type: Late-breaker
- Anonymous review and selection by part of the SCC: **February 2025**
- Outcome communicated to submitter: **21 February 2025**

### **Additional implications** (on top of/overruling the standard submission rules and regulations):

- You can only submit the abstract once to the EAU25 late-breaker submission – double submitted abstracts will not be reviewed
- Very limited places are available for late-breaking abstracts in the programme, therefore the selection will be done very critically
- Late-breaking abstracts will be reviewed anonymously by a selection of members of the Scientific Congress Committee (SCC)

### **Rules & regulations of a submitting a late-breaker abstracts**

- Abstract(s) may not have been published before the start of the Annual EAU congress in Madrid on 21 March 2025. **No encore abstracts are accepted.**
- All abstracts must be submitted in English.
- All sources of financial support (including government grants) or companies which handled the data must be filled out in the designated question during the submission procedure (and not in the abstract text). All grant funding agencies and/or company abbreviations should be spelled out. This information will be published with the full body abstract, wherever it is reproduced on the EAU's publications, channels or online.
- Accepted abstracts will be published as submitted.
- One of the authors or someone assigned by the authors should defend the abstract physically in Madrid during the session and therefore needs an on-site registration. If no one can defend the abstracts physically during the congress, the abstract will be removed from the session and no certificate of presentation will be available.
- Selected late-breaking abstracts might be considered for publication in European Urology.

### **Copyright**

- Copyright of the accepted abstract is assigned to the European Association of Urology and any conflicts with any other scientific association will be the sole responsibility of the author(s).
- All accepted abstracts, including figures and tables, are property of EAU and are protected by copyright.
- By submitting an abstract you agree (also on behalf of co-authors) to the terms of use and conditions as stated above. Please note that transfer of copyright applies to all material submitted (such as videos, slide/audio presentations, live-streams, webcasts, poster PDFs and all other materials). Moreover, the submission of an abstract affirms that all authors named in the abstract have agreed to its submission for presentation at the Annual EAU congress.
- Requests for re-use of material can be done by sending an email to [abstracts@congressconsultants.com](mailto:abstracts@congressconsultants.com) (please include the abstract code)

### **Publication**

By submitting an abstract you agree (also on behalf of (co-)authors) that the accepted abstract as well as related materials such as videos, slide/audio presentations, live-streams, webcasts, poster PDFs and any other materials are published on EAU publications and media channels.

Selected late-breaking abstracts might be considered for publication in European Urology.

## Content related instructions

### Human Experimentation

Any human experimentation conducted with respect to the submitted abstract(s), should have been conducted according to the protocol approved by the institutional or local committee on ethics in human investigation; or, if no such committee exists, the works should have been conducted in accordance with the principles of the Declaration of Helsinki of World Medical Association. Council may enquire further into ethical aspects when evaluating the abstract(s).

### Clinical Studies

In clinical studies, the authors must state that an Ethical Committee approval has been obtained.

Please note that the statement should clearly indicate whether the approval was obtained or not, accompanied by a brief explanation of the reason in case of a disapproval. This information is necessary for the proper processing of the review.

### Trial in progress

Trials in Progress abstracts offer researchers a platform to present ongoing trials, promote collaboration, and discuss correlatives and innovative trial designs. It is expected that abstracts submitted as Trial in progress are ongoing trials that have not reached any protocol-specified endpoints for analysis.

Trial in Progress abstracts should contain the following two sections and should not have data analysis available before the submission deadline.

#### **Introduction and objectives:**

Provide the scientific background and rationale of the trial, highlighting correlative studies of interest.

#### **Materials and methods:**

Detail the trial design and statistical methods, emphasizing any innovative aspects.

Outline the planned interventions and specify major eligibility criteria.

Report current enrolment without disclosing protocol-specified results.

State clinical trial registry number.

#### **Topic**

A topic has to be selected from the drop-down menu. For the review of the abstract, it is of vital importance that the correct (sub)topic, clinical step(s) and management tool(s) are selected.

## Practical instructions

### **Abstract Title**

- The title should clearly define the topic.
- There is no maximum length for the title, but the characters in the title are included in your total character count.
- The first letter of the title will automatically begin with a capital letter.
- Standard abbreviations may be used as follows: On first use spell out the full term and follow with the abbreviation in parentheses.
- Do NOT identify your institution in the title.
- Do NOT type the abstract title in capital letters.
- Do NOT end the title with a period.

- Do NOT use trademarks in the title.

### **Authors and Affiliations**

- A maximum of 24 authors per abstract is allowed.
- Each author should have contributed substantially to the represented work in terms of conceptual design or analysis, writing of the article and final approval of the article in order to take public responsibility for the content.
- An abstract presenter is limited to 5 abstract presentations.
- Please make sure to write the name of the Organisation/Institution, Department, City and Country in English (one institution per author).
- If co-authors are from the same institution, the programme will automatically copy all information into the next boxes, so you do not have to type all information again. If co-authors are not from the same institution you can edit any box as your wish.
- There is only the possibility to enter one first author, one presenting author and one last author.
- Do type family name and full first name of all authors. Do NOT type titles, degrees and institutional affiliations. Carefully check the correct spelling of all names as this will be the way that names will be published.

### **Abstract Body**

- The following headers have already been formatted for you and should not be repeated in the text fields:
  - Introduction & objectives (state the objective of the study)
  - Materials & methods (describe the material and methods)
  - Results (summarise the results presenting sufficient details to support the conclusions reached, it is NOT acceptable to state: "The results will be discussed")
  - Conclusion
- Use number to indicate values (i.e. "6" instead of "six") and only very well-known abbreviations e.g., ml, kg, MRI.
- Standard abbreviations may be used as follows: On first use spell out the full term and follow with the abbreviation in parentheses.
- To insert tables use the 'Insert table'-icon.  
To insert symbols or specific characters use the 'Symbol-icon'. Do NOT copy/paste as this will cause format problems.
- Any acknowledgements can be placed underneath the conclusion.

### **Figures**

- Upload of pictures/graphics is only possible as jpg file (counts for 500 characters).
- Upload of only 1 picture/graphic is allowed and a collage of multiple pictures is NOT allowed, because of readability. If not it will be removed from the submission.
- How to upload a jpg file:
  - Open the upload picture icon:
  - Upload new image – browse
  - Select your image
  - Click on upload
  - Your selected image will be shown in the list of Uploaded Images
  - First select the image and click on 'Insert'
  - To resize your image, please click on 'Appearance' and adjust the dimensions

### **Abstract Size**

The size of the abstract is limited to 3,000 characters (this includes title, body of abstract, spaces, tables and pictures/graphics). The submission programme will automatically calculate the size of your abstract and will not allow submissions that do not fit in the size requirements. A picture/graphic counts for 500 characters.

**Proof reading**

After you have inserted all data for your abstract submission a preview will show on your screen. Please verify that your abstract submission is correct and read this preview carefully (including author information). Keep a print for your own records.

It is the responsibility of the submitting author to ensure the abstract is in perfect order with no errors in spelling or grammar, as revisions will not be accepted. Abstracts will not be corrected.

**Late-breaking abstract review process**

All abstracts are subject to peer review and are expected to meet the standards of academic/scientific excellence. Submissions will be reviewed by the member of Scientific Congress Office whose identities will remain anonymous to the authors. Reviewers will give scores from 1 to 5 points, taking into consideration the following criteria: High scientific significance, originality, priority, quality of research methodology and data. Review and session composition will take place in February 2025. The outcome of the abstract selection is available online through the abstract submission website around 21 February 2025. You will receive a notification by email. The Scientific Congress Office reserves the right to obtain your raw data for statistical evaluation.